Thiophenylaminoimidazolines as IP antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S398000, C544S139000, C548S333100

Reexamination Certificate

active

07078401

ABSTRACT:
Methods for treatment of IP antagonist mediated diseases or conditions by administration to a subject in need thereof a compound of formula (I)wherein R1, R2, A and X are as defined herein. Also disclosed are compounds and related compositions.

REFERENCES:
patent: 4374143 (1983-02-01), Dolman et al.
patent: 4396617 (1983-08-01), Dolman et al.
patent: 6184242 (2001-02-01), Bley et al.
patent: 6417186 (2002-07-01), Jahangir
patent: 6472536 (2002-10-01), Bley et al.
patent: 6596876 (2003-07-01), Bley et al.
patent: 0 901 018 (1999-03-01), None
patent: WO 02/40453 (2002-05-01), None
Ito et al. Chem. & Pharm. Bull. 1960, 7, 605 *(CAS Abstract Attached).
Clarke, Robin D., “Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists”,Bioorganic&Medicinal Chemistry Letters, 14(4) 1053-1056, Feb. 23, 2004.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Thiophenylaminoimidazolines as IP antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiophenylaminoimidazolines as IP antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophenylaminoimidazolines as IP antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3595962

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.